GSK’s RTS,S Malaria Vaccine Study Nears the Finish Line With Fresh 2026 Update

GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.

The study, titled A Prospective Study to Evaluate the Safety, Effectiveness and Impact of the RTS,S/AS01E Vaccine in Young Children in Sub-Saharan Africa, tracks how GlaxoSmithKline’s malaria shot performs in real-life use. It focuses on safety, how well the vaccine works, and its broader impact on child health across malaria-endemic regions.

The main intervention is the RTS,S/AS01E malaria vaccine, designed to cut malaria cases and severe illness in young children. The study also involves routine blood sampling in hospitalised children to monitor safety signals and confirm suspected side effects.

The trial is observational and prospective, meaning researchers watch outcomes over time rather than assigning treatments. Children are grouped into different surveillance cohorts, and there is no masking, so both doctors and families know who received the vaccine.

The study began after first submission on 2019-02-25, marking the start of structured data collection around the vaccine rollout. The latest update on 2026-02-27 confirms that new information has been added and that GSK is still refining its long-term safety and impact picture.

The overall status is listed as completed, so core data collection is done, but results are not yet posted, which keeps some uncertainty in the market. Investors will watch closely for full results, as strong real-world data could support wider adoption and policy backing in Africa and potentially new use cases.

For GSK, positive data could reinforce its vaccines portfolio and support sentiment around long-duration revenue from malaria programs. Competitors in the malaria space, including newer entrants with mRNA or next-generation vaccines, may face a higher bar if RTS,S/AS01E shows durable safety and impact in large populations.

Policy support from global health agencies and funding bodies could translate into stable, though not hypergrowth, revenue streams that appeal to defensive healthcare investors. At the same time, any safety concerns in the final report could weigh on GSK’s stock and benefit rival developers working on alternative malaria vaccines or prevention tools.

The latest update confirms that follow-up and analysis for this RTS,S/AS01E study are current, with further details available on the ClinicalTrials portal.

To learn more about GSK’s potential, visit the GlaxoSmithKline drug pipeline page.